Eczema drug shows promise in breast cancer trial
NCT ID NCT06637306
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing whether adding dupilumab (an eczema and asthma drug) to standard immunotherapy and chemotherapy can safely improve outcomes for people with locally advanced triple-negative breast cancer. About 15 participants will receive the combination before surgery. The main goal is to check for severe immune-related side effects, while also measuring how well the treatment shrinks tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dupilumab (an eczema/asthma drug) combined with pembrolizumab (immunotherapy) and chemotherapy (paclitaxel and carboplatin)
What this could lead to
If successful, this could point toward a new treatment option for triple-negative breast cancer that may improve tumor clearance before surgery.
What could go wrong
This is a very early, small pilot trial with only 15 participants, so results may not apply broadly. The drug combination may cause severe immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TNBC, TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mount Sinai Health System
RECRUITINGNew York, New York, 10029, United States
Contact Email: •••••@•••••
Contact